WASHINGTON, D.C. — The White House announced it has reached agreements with nine more pharmaceutical giants to lower the prices of certain prescription drugs for patients who purchase them directly, without insurance, through the administration’s new TrumpRx direct-to-consumer (DTC) program, expected to launch in January 2026. 

Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi have agreed to offer Most-Favored-Nation (MFN) prices on select medicines sold through the website and will provide state Medicaid programs access to MFN pricing on their products. The companies have also made an agreement to apply MFN prices to all new innovative medicines they bring to market, though the details of how this commitment will work, including any enforcement mechanisms, remain unclear.

The White House highlighted several examples of steep discounts that would apply through TrumpRx. These include Bristol Myers Squibb lowering the price of its HIV drug Reyataz from $1,449 to $217, Novartis reducing the price of its multiple sclerosis drug Mayzent from $9,987 to $1,137, and Boehringer Ingelheim cutting the price of its type 2 diabetes medication Jentadueto from $525 to $55, among others. 

“When 47% of Americans are concerned they won’t be able to afford a health care cost next year, steps to reduce drug prices for patients are welcomed, especially by patients who rely on one of the over-priced essential medicines named in today’s announcement,” said Merith Basey, CEO of Patients For Affordable Drugs Now. “But voluntary agreements with drug companies — especially when key details remain undisclosed — are no substitute for durable, system-wide reforms. Patients are overwhelmingly calling on Congress to do more to lower prescription drug prices by holding Big Pharma accountable and addressing the root causes of high drug prices, because drugs don’t work if people can’t afford them.” 

P4ADNow also cautions against any approach that encourages drug companies to raise prices for patients in other countries. Pharmaceutical corporations already generate massive profits in every country where they sell their products. Drug corporations set and raise prices in the U.S. because Congress allows it, and increasing prices internationally will do nothing to lower prices for American patients

###

Patients For Affordable Drugs Now is the only national, patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNow is bipartisan and does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more, visit: PatientsForAffordableDrugsNOW.org